Catalyst Wire Dossier Catalyst Wire Dossier

E10030 (Anti-PDGF pegylated aptamer)

anti-PDGF pegylated aptamer · Ophthotech Corporation
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for E10030 (Anti-PDGF pegylated aptamer), covering 2014-01-03 to 2014-01-03. Get the full timeline:

Most recent: Clinical Trial Update: A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration [Phase 2]

See pricing